<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9618">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05694247</url>
  </required_header>
  <id_info>
    <org_study_id>DMS-35932</org_study_id>
    <nct_id>NCT05694247</nct_id>
  </id_info>
  <brief_title>Pivotal Study to Evaluate the Clinical Safety and Performance of the CorNeat KPro for Treatment of Corneal Blindness</brief_title>
  <official_title>A Single Arm, Pivotal, Open Label, Multicenter Clinical Investigation to Evaluate the Clinical Safety and Performance of the CorNeat Keratoprosthesis, for Treatment of Corneal Blindness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CorNeat Vision Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CorNeat Vision Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single Arm, Pivotal, Open Label, Multicenter Clinical Investigation to Evaluate the&#xD;
      Clinical Safety and Performance of the CorNeat Keratoprosthesis, for Treatment of Corneal&#xD;
      Blindness&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial will assess the clinical safety and performance of the CorNeat&#xD;
      Keratoprosthesis (KPro), a synthetic, artificial cornea for or the treatment of corneal&#xD;
      blindness in subjects who are not candidates for traditional corneal transplant.&#xD;
&#xD;
      40 subjects who are willing to take part in the study will undergo screening examinations to&#xD;
      verify their eligibility.&#xD;
&#xD;
      The CorNeat KPro will be implanted unilaterally in eligible subjects. Follow up procedures&#xD;
      will be performed at 1 day, 1 week, 2 weeks, 1, 2, 3, 4, 5, 6,8, 10,12,15,18,21 and 24 months&#xD;
      post-surgery and will include clinical assessment of the implanted eye using slit-lamp&#xD;
      biomicroscopy, intra ocular pressure measurement and ocular imaging. Additionally, subjects'&#xD;
      visual acuity will be assessed and recorded throughout the 24 months follow up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2023</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>Throughout 24 months post-op</time_frame>
    <description>The frequency of all Unanticipated Adverse Device-related Events (UADE) during and following implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention rate</measure>
    <time_frame>24 months post-op</time_frame>
    <description>The number of retained devices at the end of 24- months follow up period will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Best Corrected Distance Visual Acuity (BCDVA) from baseline</measure>
    <time_frame>Throughout 24 months post-op</time_frame>
    <description>Visual acuity will be measured with ETDRS format charts. The number of patients with BCDVA better than 6/120 at 24 months after</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Corneal Disease</condition>
  <condition>Corneal Opacity</condition>
  <condition>Corneal Injuries</condition>
  <arm_group>
    <arm_group_label>CorNeat KPro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraocular implantation of the CorNeat KPro</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CorNeat KPro</intervention_name>
    <description>The optical component of the CorNeat KPro will be implanted into a circular disc of the cornea (as performed in standard penetrating keratoplasty surgery) and the skirt component will be embedded under a 360º conjunctival flap.</description>
    <arm_group_label>CorNeat KPro</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged ≥ 21 and ≤ 80 years on the day of screening&#xD;
&#xD;
          2. Candidates must have the ability and willingness to attend all scheduled visits and&#xD;
             comply with all study procedures&#xD;
&#xD;
          3. Legally blind (BCVA of 6/120 or worse in the better eye) in one or two eyes. In case&#xD;
             of unilateral blindness - BCVA of Counting Fingers (CF) from 1 meter or worse in the&#xD;
             operated eye&#xD;
&#xD;
          4. Keratoprosthesis surgery is indicated in cases when keratoplasty is not a reasonable&#xD;
             option or following a verifiable history of prior failed corneal transplantation.&#xD;
&#xD;
          5. Indications that fall under poor candidate for keratoplasty include but are not&#xD;
             limited to: herpetic keratitis, vascularized corneal scar, Ocular Cicatricial&#xD;
             Pemphigoid, alkali burn, Steven Johnson Syndrome, and limbal stem cell deficiency;&#xD;
&#xD;
          6. Adequate tear film and lid function&#xD;
&#xD;
          7. Perception of light in all quadrants&#xD;
&#xD;
          8. Female patients of childbearing age must have negative pregnancy test at screening and&#xD;
             agree to use an effective method of contraception throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Reasonable chance of success with traditional keratoplasty&#xD;
&#xD;
          2. Current retinal detachment&#xD;
&#xD;
          3. Connective tissue diseases or severely scarred conjunctiva in the target eye&#xD;
&#xD;
          4. End stage glaucoma or evidence of current uncontrolled glaucoma&#xD;
&#xD;
          5. History or evidence of severe inflammatory eye diseases (i.e. conjunctivitis, uveitis,&#xD;
             retinitis, scleritis)&#xD;
&#xD;
          6. Active inflammation of the conjunctiva in one or both eyes&#xD;
&#xD;
          7. History of ocular or periocular malignancy&#xD;
&#xD;
          8. History of extensive keloid formation&#xD;
&#xD;
          9. Any known intolerance or hypersensitivity to topical anaesthetics, mydriatics, or&#xD;
             component of the device&#xD;
&#xD;
         10. Ocular ischemic syndrome&#xD;
&#xD;
         11. Signs of current infection, including fever and current treatment with antibiotics&#xD;
&#xD;
         12. Severe generalized disease that results in a life expectancy shorter than two years&#xD;
&#xD;
         13. Any clinical evidence that the investigator feels would place the subject at increased&#xD;
             risk with the placement of the device&#xD;
&#xD;
         14. Corneal thickness less than 400 or higher than 1,200 microns in any region of the&#xD;
             pachymetry map of the eye intended to be operated&#xD;
&#xD;
         15. Currently pregnant or breastfeeding&#xD;
&#xD;
         16. Participation in any study involving an investigational drug or device within the past&#xD;
             30 days or 5 half-lives of the drug (whichever longer) or ongoing participation in a&#xD;
             study with an investigational drug or device&#xD;
&#xD;
         17. Intraoperative complication that would preclude implantation of the study device&#xD;
&#xD;
         18. Hemoglobin A1C (HbA1c) higher than 8% at screening indicating unbalanced diabetes&#xD;
             and/or target organ damage associated with diabetes&#xD;
&#xD;
         19. Patients requiring anticoagulation treatment, which cannot be interrupted for the&#xD;
             surgical procedure&#xD;
&#xD;
         20. Vulnerable populations - minors, pregnant women, prisoners, sponsor or study&#xD;
             institution employees, military persons, terminally ill, comatose, physically and&#xD;
             intellectually challenged individuals, institutionalized patients and refugees&#xD;
&#xD;
         21. Subjects with corneal disorders located outside the central 7 mm, such as Mooren&#xD;
             ulcer, peripheral ulcerative keratitis, and necrotizing herpetic keratitis (if located&#xD;
             outside the central 7 mm of the cornea)&#xD;
&#xD;
         22. Patients with a functioning trabeculectomy or existing Microinvasive Glaucoma Surgery&#xD;
             (MIGS) device that shunts aqueous from the anterior chamber into the subconjunctival&#xD;
             space&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerry Tal, B.Sc, MBA</last_name>
    <phone>+972 52-356-2826</phone>
    <email>gerry@corneat.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ido Klein, B.Sc, MBA</last_name>
    <phone>+972549350507</phone>
    <email>ido@corneat.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3N9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Alfonso Iovieno, M.D</last_name>
      <phone>604 875 4555</phone>
    </contact>
    <investigator>
      <last_name>Alfonso Iovieno, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UHN - University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Judy Hung, BAT Ind.Des., OA</last_name>
      <phone>(416) 603-5800</phone>
      <phone_ext>3106</phone_ext>
      <email>judy.hung@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Clara Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Rootman, MD, FRCS(C)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Hannah Croudy</last_name>
      <phone>04 67 33 79 62</phone>
      <email>h-CROWDY@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Daien, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Fondation Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick Vachey</last_name>
      <phone>0148036433</phone>
      <email>pvachey@for.paris</email>
    </contact>
    <investigator>
      <last_name>Eric Gabizon, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson</name>
      <address>
        <city>Petah tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Hilla German</last_name>
      <phone>9723-9376100</phone>
      <email>eyeclinic@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Irit Bahar, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eitan Livni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC - Location AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Monique Wezel</last_name>
      <phone>+31205668618</phone>
      <email>m.wezel@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Ruth Lapid-Gortzak, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Israel</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 12, 2023</study_first_submitted>
  <study_first_submitted_qc>January 12, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2023</study_first_posted>
  <last_update_submitted>January 12, 2023</last_update_submitted>
  <last_update_submitted_qc>January 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Corneal Injuries</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
    <mesh_term>Corneal Opacity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

